Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis-Reference-Cited by-同舟云学术

Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis

Author:

Langley R.G.¹,Rich P.²,Menter A.³,Krueger G.⁴,Goldblum O.⁵,Dutronc Y.⁵,Zhu B.⁵,Wei H.⁵,Cameron G.S.⁵,Heffernan M.P.⁵

Affiliation:

1. Division of Clinical Dermatology and Cutaneous Science; Department of Medicine; Dalhousie University; Halifax NS Canada

2. Department of Dermatology; Oregon Health & Science University School of Medicine; Portland OR USA

3. Department of Dermatology; University of Texas Southwestern Medical Center Southwestern Medical School; Dallas TX USA

4. Department of Dermatology; University of Utah School of Medicine; Salt Lake City UT USA

5. Eli Lilly and Company; Indianapolis IN USA

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

Reference29 articles.

2. Nail psoriasis, the unknown burden of disease;Klaassen;J Eur Acad Dermatol Venereol,2014

4. A 36-week retrospective open trial comparing the efficacy of biological therapies in nail psoriasis;Bardazzi;J Dtsch Dermatol Ges,2013

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献